Bruce A. Littlefield

4.4k total citations
72 papers, 3.0k citations indexed

About

Bruce A. Littlefield is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, Bruce A. Littlefield has authored 72 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 26 papers in Molecular Biology and 14 papers in Cell Biology. Recurrent topics in Bruce A. Littlefield's work include Cancer Treatment and Pharmacology (22 papers), Microtubule and mitosis dynamics (14 papers) and Protease and Inhibitor Mechanisms (8 papers). Bruce A. Littlefield is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Microtubule and mitosis dynamics (14 papers) and Protease and Inhibitor Mechanisms (8 papers). Bruce A. Littlefield collaborates with scholars based in United States, Japan and Spain. Bruce A. Littlefield's co-authors include Mary Ann Jordan, Leslie Wilson, Murray J. Towle, Tatiana Okouneva, Melvin J. Yu, Olga Azarenko, Yoshito Kishi, Bryan M. Lewis, Galina Kuznetsov and Herbert P. Miller and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Bruce A. Littlefield

71 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce A. Littlefield United States 28 1.4k 1.0k 426 419 396 72 3.0k
Junji Magae Japan 33 841 0.6× 1.9k 1.9× 193 0.5× 690 1.6× 251 0.6× 136 3.7k
Brigitte Marian Austria 36 1.1k 0.8× 2.3k 2.2× 252 0.6× 664 1.6× 432 1.1× 111 3.8k
G. Tim Bowden United States 33 828 0.6× 2.3k 2.3× 442 1.0× 930 2.2× 164 0.4× 91 3.9k
Quansheng Zhou China 37 640 0.5× 2.3k 2.3× 366 0.9× 519 1.2× 200 0.5× 89 3.7k
Mee‐Hyun Lee South Korea 33 739 0.5× 2.4k 2.4× 262 0.6× 546 1.3× 356 0.9× 130 3.8k
Carmen Blanco‐Aparicio Spain 31 936 0.7× 2.6k 2.5× 197 0.5× 590 1.4× 309 0.8× 79 3.9k
Nadine Darwiche Lebanon 33 400 0.3× 2.3k 2.2× 344 0.8× 819 2.0× 217 0.5× 98 3.6k
Amy Roshak United States 24 658 0.5× 1.2k 1.1× 258 0.6× 444 1.1× 110 0.3× 41 2.3k
Shiow‐Lin Pan Taiwan 37 634 0.5× 2.2k 2.2× 148 0.3× 470 1.1× 894 2.3× 148 3.8k
Yoshihiro Sowa Japan 30 968 0.7× 2.9k 2.9× 99 0.2× 440 1.1× 222 0.6× 88 3.7k

Countries citing papers authored by Bruce A. Littlefield

Since Specialization
Citations

This map shows the geographic impact of Bruce A. Littlefield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce A. Littlefield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce A. Littlefield more than expected).

Fields of papers citing papers by Bruce A. Littlefield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce A. Littlefield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce A. Littlefield. The network helps show where Bruce A. Littlefield may publish in the future.

Co-authorship network of co-authors of Bruce A. Littlefield

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce A. Littlefield. A scholar is included among the top collaborators of Bruce A. Littlefield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce A. Littlefield. Bruce A. Littlefield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Zhijie, Judith A. Ermer, Ji Li, et al.. (2025). Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity. EMBO Molecular Medicine. 17(5). 1071–1100. 2 indexed citations
2.
Bellio, Chiara, Albert Gris‐Oliver, Françesc Canals, et al.. (2022). GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers. 14(10). 2562–2562. 12 indexed citations
3.
Woźniak, Agnieszka, Bram Boeckx, Elodie Modave, et al.. (2021). Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma. Clinical Cancer Research. 27(11). 3106–3115. 8 indexed citations
4.
Cortés, Javier, Patrick Schöffski, & Bruce A. Littlefield. (2018). Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treatment Reviews. 70. 190–198. 56 indexed citations
5.
Rickles, Richard J., Junji Matsui, Ping Zhu, et al.. (2015). Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin- Insensitive Tumor Cells. 1(1). 9–17. 1 indexed citations
6.
Towle, Murray J., K. Nomoto, Makoto Asano, et al.. (2012). Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.. PubMed. 32(5). 1611–9. 38 indexed citations
7.
Wozniak, Krystyna M., K. Nomoto, Rena G. Lapidus, et al.. (2011). Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice. Cancer Research. 71(11). 3952–3962. 75 indexed citations
8.
Xu, Qunli, Kuan‐Chun Huang, Karen TenDyke, et al.. (2011). In vitro and in vivo anticancer activity of (+)-spongistatin 1.. PubMed. 31(9). 2773–9. 17 indexed citations
9.
Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. Bioorganic & Medicinal Chemistry Letters. 21(6). 1634–1638. 12 indexed citations
10.
Towle, Murray J., Kathleen A. Salvato, Bruce F. Wels, et al.. (2010). Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions. Cancer Research. 71(2). 496–505. 111 indexed citations
11.
Kuznetsov, Galina, Qunli Xu, Karen TenDyke, et al.. (2009). Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Molecular Cancer Therapeutics. 8(5). 1250–1260. 85 indexed citations
12.
Wu, Jiayi, K. Nomoto, John Wang, et al.. (2009). Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts. Cancer Research. 69. 3687–3687. 3 indexed citations
13.
Kuznetsov, Galina, Karen TenDyke, Melvin J. Yu, & Bruce A. Littlefield. (2007). Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Molecular Cancer Therapeutics. 6. 40 indexed citations
14.
Kowalczyk, James J., Mark R. Spyvee, Yang Hu, et al.. (2005). Synthetic analogs of the marine natural product hemiasterlin: Optimization and discovery of E7974, a novel and potent antitumor agent. Cancer Research. 65. 282–282. 3 indexed citations
15.
Agoulnik, Sergei, Galina Kuznetsov, Karen TenDyke, et al.. (2005). Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell lines. Journal of Clinical Oncology. 23(16_suppl). 2012–2012. 9 indexed citations
16.
Rudolph‐Owen, Laura A., Kathleen A. Salvato, Hongsheng Cheng, et al.. (2004). A 96-well plate cell-based assay to quantify undesired cytotoxic effects against quiescent non-dividing cells. Cancer Research. 64. 264–265. 3 indexed citations
17.
Okouneva, Tatiana, Leslie Wilson, Bruce A. Littlefield, & Mary Ann Jordan. (2004). E7389 and ER-076349, synthetic halichondrin B analogs, suppress centromere dynamics in concert with mitotic block. Cancer Research. 64. 1255–1255. 2 indexed citations
18.
Wang, Yuan, et al.. (2000). Structure–activity relationships of Halichondrin B analogues: modifications at C.30–C.38. Bioorganic & Medicinal Chemistry Letters. 10(10). 1029–1032. 41 indexed citations
19.
Bridges, Alexander J., Arthur Lee, C. Schwartz, Murray J. Towle, & Bruce A. Littlefield. (1993). The synthesis of three 4-substitutedbenzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorganic & Medicinal Chemistry. 1(6). 403–410. 22 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junji Magae Breakdown of academic impact, for papers by Brigitte Marian Breakdown of academic impact, for papers by G. Tim Bowden Breakdown of academic impact, for papers by Quansheng Zhou Breakdown of academic impact, for papers by Mee‐Hyun Lee Breakdown of academic impact, for papers by Carmen Blanco‐Aparicio Breakdown of academic impact, for papers by Nadine Darwiche Breakdown of academic impact, for papers by Amy Roshak Breakdown of academic impact, for papers by Shiow‐Lin Pan Breakdown of academic impact, for papers by Yoshihiro Sowa
Rankless by CCL
2026